Information Provided By: 
Fly News Breaks for July 28, 2015
CPHD
Jul 28, 2015 | 07:15 EDT
After Cepheid launched its GeneXpert Omni, Wells Fargo thinks the product could surpass the competition and make the company the dominant molecular player in the point-of-care market. The firm says the Omni, along with other new products, conservative increase the company's addressable market to over $8B by 2020. Wells keeps an Outperform rating on the shares.
News For CPHD From the Last 2 Days
There are no results for your query CPHD
